EGFR and non-small cell lung carcinoma: Based on these data, the ARCHER 1050, a phase III, open label trial has been designed to compare the efficacy of first line dacomitinib versus gefitinib in 440 EGFR mutant patients with stage IIIB/IV NSCLC.